SUMMARY Antacids are widely used in the management of duodenal ulcer but the optimum dose of antacid required for ulcer healing has not been determined. We therefore studied 107 patients with endoscopically diagnosed duodenal ulcer who were allotted at random to one of the following treatment groups; placebo (group P) and antacid (groups A, B and C). A liquid antacid (Aludrox MH, Wyeth) with neutralising capacity of 2-3 mmol HCI/ml was administered in graded doses of 7.5 ml (Group A), 15 ml (Group B), and 30 ml (Group C), one hour and three hours after each meal, six times a day for four weeks. Patients in group P received 15 ml liquid placebo in a similar fashion. Complete symptomatic relief was obtained in 33% of patients in the placebo group, 54% in antacid group A, 89% in group B, and 92% in group C. Endoscopic assessment at the end of four weeks of treatment gave an ulcer healing rate of 29% in the placebo group, 46% in group A (103.5 mmol antacid/day), 85% in group B (207 mmol/day), and 88% in group C (414 mmol/day). There was no significant difference in the healing rates and pain relief between placebo and antacid group A, while both groups B and C had significantly higher ulcer healing rates and pain relief compared with placebo (p<0-001) and antacid group A (p<001). Drug related unwanted effects were recorded only in group C -28% of patients suffered from diarrhoea. It is concluded that the optimum antacid requirements for the treatment of duodenal ulcer is 90 ml (acid neutralising capacity, 207 mmol HCI) per day.
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It is well established that antacids used in large doses (210 ml/day; neutralising capacity 800-1000 mmol HCl/day) and at fixed intervals (one hour and three hours after meals, and at bed time) promote Table 2 . At the end of first week symptomatic response to treattment was poor in placebo and antacid group A; only 8%'c and 12% being relieved of pain in the two groups respectively. In contrast, 52%lc and 63% of patients in groups B and C respectively were completely asymptomatic. The same trend continued during the whole period of study. At the end of four weeks there was no significant difference in relief of pain between the placebo-treated patients and antacid (Figure) . There was no significant difference in the healing rates between placebo and group A, while healing rates in groups B and C were significantly superior compared with placebo (p<O-OOl) and group A (p<0.01). There was no significant difference in the healing rates between groups B and C. 
